AzTrials
AzTrials

ObesityIMPACT ObesityNCT01116375

Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control?

An observational study of Obesity and Obstructive Sleep Apnea, run by Katz, Sherri Lynne, M.D. at 4 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To determine whether, in obese children with moderate-severe Obstructive Sleep Apnea who are prescribed Positive Airway Pressure(PAP) therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR Read more about this study

Who is it for?
Ages 8 to 16 years
Conditions the study is for
Obesity, Obstructive Sleep Apnea
How many people
27 participants
Where
4 sitesCanada
Study dates
Jun 2010to Sep 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Obese children (body mass index (BMI) ≥ 95th %ile for age and sex) 8-17 years old with moderate-severe OSA will be recruited for this study from four pediatric tertiary care centres across Canada. As per current standard of care, those children with moderate-severe OSA, defined as ≥ 10 obstructive events per hour on polysomnography, will be prescribed PAP treatment.

Who may be able to join

  • Age 8 to 16 years
  • Obesity, defined as body mass index greater than or equal to the 95th percentile for gender and age (2000 CDC Growth Charts for US)
  • Moderate to severe OSA diagnosed on polysomnography, for which PAP therapy (continuous positive airway pressure or bi-level positive airway pressure) is prescribed by a physician. Overnight laboratory polysomnography, the gold standard for assessment of OSA115 and titration of PAP, will be performed and scored by a certified sleep technician, according to the American Academy of Sleep Medicine recommendations. Moderate to severe OSA will be defined as an obstructive apneahypopnea index (OAHI) of greater than or equal to 10 apneas or hypopneas per hour. Although no strict guidelines for defining severity of OSA in children exist, the definition for this study was derived by a consensus of pan-Canadian pediatric sleep medicine experts.
  • Parents/guardians and children must also be fluent in English or French.

Who cannot join

  • craniofacial anomalies other than tonsillar and adenoid enlargement118, 119
  • central nervous system lesions
  • neuromuscular, neurological, or genetic syndromes
  • congenital heart disease and/or diagnosed ventricular dysfunction
  • chronic respiratory disease with the exception of asthma
  • use of oral or intravenous corticosteroids within the past 3 months (as this would affect the primary outcome).
  • prior exposure to PAP therapy

Trial locations and contacts

4 sites in 1 country.

Canada4 sites
  • Alberta Children's Hospital

    Calgary, Alberta

  • Stollery Children's Hospital

    Edmonton, Alberta

  • Montreal Childrens Hospital

    Montreal, Quebec

  • Childrens Hospital of Eastern Ontario

    Ottawa, Ontario

Other trials in Canada

About this study

Official title: Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control? A Multi-Centered Prospective Cohort Study

To determine whether, in obese children with moderate-severe Obstructive Sleep Apnea who are prescribed Positive Airway Pressure(PAP) therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR

Read the detailed description

Rationale: The five-fold increase in prevalence of childhood obesity in Canada over the last 15 years has led to an increasing number of pediatric cases of obesity-related obstructive sleep apnea (OSA). Not only is the prevalence of OSA significantly higher among obese children compared with the general population, but in this group, routine treatment by adenotonsillectomy has a much lower cure rate. Instead, Positive Airway Pressure (PAP) treatment is usually prescribed. Other complications of obesity are also increasingly recognized in children, including metabolic disturbances with insulin resistance (IR). This is particularly concerning, since IR is an identified surrogate measure of future obesity-related sequelae, such as diabetes, dyslipidemia, cardiovascular disease (including hypertension, and heart rate disturbances), inflammation and impaired quality of life. Of particular interest, the IR related to obesity can be exacerbated by OSA and the severity of IR correlates with the severity of OSA. IR is measured using a homeostasis model assessment of insulin resistance (HOMA-IR) and is calculated from fasting blood glucose and insulin levels. In obese adults with OSA, HOMA-IR, as well as cardiovascular and other metabolic markers, has been shown to improve following PAP therapy. Such a study has not been done in children. We hypothesize that PAP treatment for obese children with moderate-severe OSA will improve markers of obesity-related disease.

Primary Objective: To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR. Secondary Objectives: To determine whether increased hours of PAP usage per night is associated with a greater improvement in the following outcomes: 1) sympathetic nervous system activation (systolic and diastolic hypertension, nocturnal hypertension, heart rate and heart rate variability); 2) inflammation 3) neurobehavioral and quality of life measures. Methods: Study design: prospective multi-centre cohort study. Study Population: Obese children (body mass index (BMI) ≥ 95th %ile for age and sex) 8-17 years old with moderate-severe OSA will be recruited for this study from four pediatric tertiary care centres across Canada. As per current standard of care, those children with moderate-severe OSA, defined as ≥ 10 obstructive events per hour on polysomnography, will be prescribed PAP treatment. Sample Size: We expect a medium effect size (0.5); therefore 10 subjects per parameter tested (n=4) in the regression model and 25% attrition requires the recruitment of 54 subjects. Measurements will be made at baseline and 12 months. Data collection will include HOMA-IR, 24-hr blood pressure measurements, electrocardiogram for heart rate and heart rate variability, C-reactive protein as a marker of inflammation, neurobehavioral/quality of life measures (Conners parent and teacher scales, Child Behavior Checklist and Pediatric Quality of Life Inventory) and physical activity questionnaire (Habitual Activity Estimation Scale (HAES)). Data Analysis: Multivariate linear regression analyses will be performed for our primary and secondary outcomes. Our dependent variable will be change in HOMA-IR; our primary independent variable will be average number of hours/night of PAP usage. Adjustment variables will be change in BMI %ile, pubertal stage (Tanner stage 1-2 vs.

3-5), and change in HAES. Similar analyses will be performed for our secondary outcomes.

Importance: Treatment of obesity-related OSA in adults has been shown to reduce morbidity and mortality. Our study is uniquely poised and timely, as it will be the first to examine the impact of PAP therapy in children on measures of insulin resistance and other obesity-related conditions. It will raise awareness of co-morbidities of obesity and OSA in childhood and support early intervention, before irreversible end-organ damage has occurred.

Keywords
Obesity, OSA, PAP therapy
Medical subject headings
Obesity, Sleep Apnea, Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01116375
Study groupRoleWhat they receive
Obese children with OSATo determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HOMA-IR

    Euglycemichyperinsulinemic clamp technique is the gold standard measurement technique for insulin resistance however, invasive and rarely used in clinical practice. A surrogate is the homeostasis model assessment (HOMA) formula for insulin resistance (HOMA-IR) Thus, lower HOMA values indicate higher insulin sensitivity. The estimate obtained with HOMA correlates well with measures of insulin resistance obtained from obese and non-obese children and adolescents with the clamp technique

    Measured: 1 year after start of PAP therapy

Secondary outcomes (6)
  1. Systemic Hypertension

    Systemic hypertension,will be measured with 24-hour ABPM at baseline and 1 year. Summary measures for each of the day and night periods include average systolic and diastolic BP, and systolic and diastolic BP loads, as well as % nocturnal dipping. These summary measures have been shown to predict important outcomes including left ventricular hypertrophy, cardiovascular events, and death more accurately than casual BP measures

    Measured: 1 year after start of treatment with PAP

  2. Heart rate and heart rate variability

    Heart rate and heart rate variability will be analyzed from electrocardiography (EKG) data acquired during polysomnography performed at baseline and 1 year. EKG is more accurate than pulse oximetry to measure high- and low-frequency variability in heart rate and thus is the gold standard for obtaining these measures during sleep.We will focus on the RR interval as a measure of heart rate. Both time-domain components and frequency-domain components will be considered as measures of heart rate variability. We will use normative values as derived by Massin et al.

    Measured: 1 year after the start of PAP therapy

  3. hsCRP

    Blood samples obtained at baseline, 6 months and 1 year will be assessed for levels of CRP, a protein which is released during the chronic inflammation underlying atherosclerosis. Compared with the standard CRP test, the hsCRP assay can detect lower protein concentrations with greater sensitivity and achieves better specificity for predicting vascular events

    Measured: 1 year after start of PAP therapy

  4. Conners' Parent and Teacher Rating Scales

    The Conners' Parent and Teacher Rating Scales have demonstrated excellent reliability and validity. These commonly used questionnaires rely on observer ratings to assess attention deficit/hyperactivity disorder (ADHD) and evaluate problem behaviour in children and adolescents. We will use the Revised Short version which contains 27 items with scales measuring oppositional behaviour, cognitive problems/inattention and symptoms of ADHD

    Measured: 1 Year fter the start fo PAP therapy

  5. Child Behavior Checklist

    The Child Behavior Checklist is one of the most widely-used standardized measures in child psychology for evaluating maladaptive behavioural and emotional problems in children Specifically, this parent-report questionnaire contains 118 items aimed at assessing the frequency of observed internalizing (i.e. anxious, depressive, and overcontrolled) and externalizing (i.e. aggressive,hyperactive, noncompliant, and undercontrolled) behaviors.

    Measured: 1 year after start of PAPA therapy

  6. Pediatric Quality of Life Inventory (PEDS-QL)

    The PEDS-QL is a 23-item test designed to evaluate levels of functioning in 4 areas of health: physical, emotional, social and scholastic. This tool has demonstrated excellent reliability and validity and is frequently used to assess pediatric quality of life.

    Measured: 1 Yaer after start of PAP therapy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 May 2010 (estimated)
  2. Study startJun 2010
  3. Primary completionJul 2014
  4. Study completionSep 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01116375
Sponsor's protocol ID
1234
Acronym
IMPACT Obesity
Status last verified
Mar 2018
First submitted
30 Apr 2010
Last updated
9 Mar 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity and Obstructive Sleep Apnea, run by Katz, Sherri Lynne, M.D. at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HOMA-IR (time frame: 1 year after start of PAP therapy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2018; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in